Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity

摘要

Objectives. It is important to develop effective therapies in minorities to ensure equity in cancer care. Underrepresentation of minorities in early phase trials may cause therapies that are effective only in majority populations. We evaluated minority participation in gynecologic oncology phase 1 clinical trials.